Purpose:Evaluate the prognostic factors in invasive vulvar cancer.Methods:Fifty one cases with invasive vulvar cancer admitted in our hospital from 1980 to 1999 were retrospectively analyzed.Results:Thirty six patients had squamous cell carcinoma and 27 of them were well differentiated and 6 moderately differentiated and 3 poorly differentiated ,three had adenocarcinoma, three had basal cell carcinoma ,three had leimyosarcoma , six had malignant melanoma. Thirteen cases (25.4%) were in FIGO stage Ⅰ;29 (56.7%) in stage Ⅱ;7(13.1%) in stage Ⅲ and 2(3.9%) in stage Ⅳ. The 5-year survival rates of stage Ⅰ,Ⅱ,ⅢandⅣwere 81.5% , 68.4% , 41.2% and 0.0% (P

Objective:To construct a EGFP(Enhanced green fluorescent protein)-labled euk-aryotic expression plasmid of Fcy::Fur suicide gene and to detect its expression in SKOV3 cell line. Methods:With the technology of gene re-arrangement,Fcy::Fur gene in pORF-Fcy:Fur plasmid was subcloned into pEGFP-N1 vector,with its correctness evaluated by the means of r-estriction enzyme analysis and sequencing.It was transfected into SKOV3 cells with lipofectin,the transient expression of GFP was observed under flu- orescence microscope after 24 hours and detected by Western blot. Results:Correct construction of pEGFP-N1-Fcy::Fur was identi- fied by methods of restriction enzyme analysis and nucleotide sequence determination.A total of 60% transfe-cted cells emitted out green fluorescence under fluorescent microscope after 24 h after transfecti-.on. Fcy::Fur gene expressed by the transfected cells were testified by Western blot. Conclusion:The recombinant eukaryotic expression vectors have been constructed successfully and effec- tive-ly expressed in ovarian cancer cells,which may provide an experimental basis for gene therapy of ovarian cancer.

Objective To investigate the expression of HA117 in bone marrow mononuclear cells (BMMNCs) of acute leukemia patients, and its correlation with multidrug resistance( MDR), as well as its correlation with antigens presentation and its clinical significance. Methods HA117 gene expressions in 36 patients with acute myeloid leukemia (AML) and 14 patients with acute lymphocytic leukemia (ALL),10 patients with idiopathic thromnocytopenic purpura (ITP) were tested by using reverse transcriptase polymerase chain reaction (RT-PCR) technique. Thirty bone marrow specimens of AML patients at different phase were selected, and immunophenotypes were assayed by flow cytometry. ResultsThere was no significant difference ( P ＞ 0.05 ) in HA117 gene expression between ALL (78.57％) and A ML (72.22％). The expressions of HA117 gene in both ALL and AML were significantly higher than in ITP patients ( P ＜ 0.05 ). The HA117 gene was expressed in 75.00％ of the initially diagnosed patients and 77.78％ of the remission patients and 69.23％ of the nonremission patients, all of them had higher expression than the patients with ITP, but there was no significant difference among the three groups. There were 47.06％ and 87.88％ with HA117 gene expressioned in non-resistance group and resistance group respectively, and the difference between the two groups was significant(P=0.005). HA117 had positively correlation with CD11b(OR =0.59, P=0. 001 ),CD33(OR=0.704, P=0. 000) expression in 30 patients of AML, and had negative correlation with MPO (OR=－0.611, P=0.001). ConclusionHA117 gene overexpression is significantly associated with the clinical resistance. It may also be associated with MDR of acute leukemia. HA117 gene can be used as an important indicator for investigating clinical MDR and predicting prognosis of acute Ieukemia patients. HA1 17 is closely related to CD11b, CD33, MPO expression in AML, and they can be used as biomarkers for evaluating therapy efficacy in AML.

Many studies indicate that macrophage migration inhibition factor(MIF)is over-expressed in tumor cells,and is involved in the carcinogenesis and tumor development by multiple methods and ways.The complicated molecular mechanisms are not quite clear,and the studies about MIF in digestive tumors,especially in hepatic cell carcinoma become more and more.

Objective To explore NF-κB(P65)expression in breast cancer and its clinical significance.Methods Immunohistochemical staining was used to examine the expression of NF-κB(P65)and its relationship with related elinicopathological factors were analyzed in eighty-seven IDC(invasive ductal cancinoma).Results NFκB(P65)expression was significantly correlated with lower tumor grading,maxilary lymph node metastasis,later TNM styng and HER-2 positive(all P＜0.05),but not with tumor size,age of the patient and the state of ER、PR.Conclusion NF-κB(P65)should be risk factors of poor prognosis in IDC.

Objective To study the effect of rosiglitazone (RSG), the agonist of peroxisome proliferator activated receptor γ (PPARγ), on the proliferation and differentiation of rat osteoblasts and the related mechanisms. Methods The identification of rat primary osteoblasts was performed by alkaline phosphatase (ALP) staining and mineralized nodules. The 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay and p-nitrophenyl phosphate (PNPP) assay were used to observe the effects of different concentrations of RSG on proliferation and differentiation of the osteoblasts. The reverse transcription polymerase chain reaction (RT-PCR) were used to detect the expression of connective tissue growth factor (CTGF) mRNA. The effects of the different concentrations (0,1,2,5,10 and 20 μmol/L) of RSG on TGF-β1-induced CTGF mRNA expression in osteoblasts were detected. Results (1)Different concentrations of RSG could not change the proliferation of osteoblasts (P＞0. 05). (2)Compared with control group, all different concentrations of RSG could suppress ALP activity in osteoblasts (P＜0. 01 ). (3) RSG suppressed the osteoblats CTGF mRNA expression induced by TGF-β1 in a dose-dependent manner (P＜0. 01). Conclusions In vitro, RSG can inhibit the TGF-β1 induced rat osteoblasts CTGF mRNA expression. RSG may play a potential role in preventing the differentiation of the rat osteoblasts.

Epstein-Barr Virus (EBV) is the first human virus related to oncogenesis.EBV infection is associated with inflammatory bowel disease (IBD) with unknown causality.The prevalence of EBV in intestinal tissue from patients with IBD is significantly higher and related to the exacerbation of the disease and refractory IBD.Immunosuppressive therapy has improved outcomes associated with IBD.However,it is also associated with an increased risk of opportunistic infection,and lymphoproliferative disorders (LDs) maybe due to EBV infection.Here we review our current understanding of the pathogenesis of EBV infection in colonic mucosal inflammation,EBV-induced disease exacerbation,lymphomagenesis in IBD,and clinical approaches therefrom.

Objective To compare the clinical effect and safety of two kinds of quadruple therapy on the basis of omeprazole and rabeprazole in the treatment of patients with active gastric ulcer and Hp positive.Methods 104 patients with active gastric ulcer and Hp positive were chosen,and they were randomly divided into two groups including A group (52 patients)with omeprazole treatment,and B group (52 patients)with rabeprazole treatment on the basis of amoxicillin +clarithromycin +bismuth potassium citrate.The clinical efficacy,clinical symptom remission rate in 7d,14d and 28d after treatment,HP eradication rate,recurrence rate with follow -up and adverse reaction inci-dence of 2 groups were compared.Results The clinical cure rate of B group was significantly higher than A group (36.54% vs.19.23%)(χ2 =8.74,P <0.05).There was no significant difference in the clinical total effective rate between the two groups(P <0.05).The clinical symptom remission rates in 7d and 14d after treatment of B group were significantly higher than A group(96.15% vs.76.92%,96.15% vs.78.85%,98.08% vs.82.69%;98.08%vs.84.62%,100.00% vs.82.69%,100.00% vs.88.46%)(χ2 =8.74,7.20,7.91;7.05,6.86,6.33;all P <0.055).The Hp eradication rate of B group was significantly higher than A group(92.31% vs.73.07%)(χ2 =9.24,P <0.05).The recurrence rate of B group was significantly lower than A group(7.69% vs.25.00%)(χ2 =10.62,P <0.05).The incidence rate of adverse reaction of B group was significantly lower than A group(3.85% vs. 13.46%)(χ2 =7.85,P <0.05).Conclusion Compared with omeprazole,quadruple therapy on the basis of rabe-prazole in the treatment of patients with active gastric ulcer and Hp positive can effectively relieve the digestive symp-toms,promote ulcer repair process,higher the Hp removal effects,prevent the long -term recurrence and is helpful to reduce the adverse drug reactions risk.

Objective To investigate the clinical effect of cefoperazone sodium and sulbactam sodium. Methods 56 cases who used cefoperazone sodium and sulbactam sodium for anti -infection were selected as the observation group,and 56 hospitalized patients who used cephalosporin ceftazidime were selected as the control group. The observation group was intravenously injectioned cefoperazone sodium and sulbactam sodium,the control group received intravenous ceftazidime.The clinical efficacy and adverse reactions of the two groups were compared.Results After treatment,the cure rate and total effective rate of the observation group were 55.36%,98.21%,which of the control group were 35.71%,91.07%.The cure rate of the observation group was significantly higher than that of the control group (χ2 =4.356,P <0.05),and the total effective rate between the two groups had no statistically signifi-cant difference (χ2 =2.817,P >0.05).The incidence rate of adverse reactions of the two groups had no significant difference.Conclusion Cefoperazone sodium and sulbactam sodium therapy has good clinical efficacy in the treat-ment of infectious diseases,and has low incidence of adverse reactions,good safety,which can be popularized and applied in clinic.

With the deepening of the lung cancer molecular biology research,small molecular targets antitumor drugs make breakthrough progress,the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is one of the most attention drug.A series studies show that EGFR-TKI can enhance the antitumor activity of ionizing radiation.Therefore,EGFR-TKI combined with radiotherapy alone for poor-risk patients appears survival benefit,but can't ignore the lung toxicity.However,there is a big contro-versy that EGFR-TKI combined with chemoradiotherapy for locally advanced NSCLC.